Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study
暂无分享,去创建一个
C Metcalfe | F. Hamdy | D. Neal | J. Donovan | K. Tilling | C. Metcalfe | J. Lane | H. Kynaston | P. Powell | K Tilling | D E Neal | F Hamdy | P Powell | J L Donovan | M. Davis | M Davis | J A Lane | R M Martin | H Kynaston | R. Martin
[1] L. Carlson,et al. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance , 2007, BJU international.
[2] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[3] P. Carroll,et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. , 2007, The Journal of urology.
[4] C. Bangma,et al. Watchful waiting in prostate cancer: review and policy proposals , 2003, BJU international.
[5] Hans Garmo,et al. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. , 2010, European urology.
[6] Joannie T. Yeh,et al. Comparison of methods for calculating prostate specific antigen velocity. , 2006, The Journal of urology.
[7] C. Parker. Active surveillance: towards a new paradigm in the management of early prostate cancer. , 2004, The Lancet. Oncology.
[8] A. Stephenson,et al. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. , 2004, Urology.
[9] F. Hamdy,et al. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. , 2006, The Journal of urology.
[10] R. Eeles,et al. Early outcomes of active surveillance for localized prostate cancer , 2005, BJU international.
[11] L. Klotz. Active surveillance for favorable risk prostate cancer: rationale, risks, and results. , 2007, Urologic oncology.
[12] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[13] J. Donovan,et al. Establishing normal reference ranges for PSA change with age in a population‐based study: The Krimpen study , 2006, The Prostate.
[14] Jenny Donovan,et al. Screening for prostate cancer , 1993, JAMA.
[15] J. Sterne,et al. Multilevel growth curve models with covariate effects: application to recovery after stroke , 2001, Statistics in medicine.
[16] J. Bosch,et al. Prostate specific antigen in a community‐based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index, and symptoms of prostatism , 1995, The Prostate.
[17] D Gillatt,et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. , 2003, Health technology assessment.
[18] R. V. D. van den Bergh,et al. Prospective validation of active surveillance in prostate cancer: the PRIAS study. , 2007, European urology.
[19] R. V. D. van den Bergh,et al. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. , 2008, European urology.
[20] F. Hamdy,et al. Screening for Prostate Cancer , 2006 .
[21] D. Dearnaley,et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival , 2006, British Journal of Cancer.